Regulation of melanoma epitope-specific cytolytic T lymphocyte response by immature and activated dendritic cells, in vitro

Cancer Research

Volumn 63, Issue 17, 2003, Pages 5607-5614

  Mehrotra, Shikhar ^a   Stevens, Robert ^a   Zengou, Ryan ^a   Chakraborty, Nitya G ^a   Butterfield, Lisa H ^b   Economou, James S ^b   Dorsky, David I ^a   Mukherji, Bijay ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; EPITOPE; MELAN A; TUMOR ANTIGEN;

ACCESSORY CELL; ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL MATURATION; CELLULAR IMMUNITY; CLONAL ANERGY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DESIGN; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; MELANOMA; PRIORITY JOURNAL;

AUTOANTIGENS; DENDRITIC CELLS; EPITOPES; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; MELANOMA; NEOPLASM PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0141704513     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Banchereau, J., and Steimnan, R. M. Dendritic cells and control of immunity. Nature, 392: 245-252, 1998.
2. Guermonprez, P., Valladeau, J., Zitvogel, L., Thery, C., and Amigorena, S. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol., 20: 621-667, 2002.
3. Young, J. W., and Inaba, K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med., 183: 7-11, 1996.
4. Parmiani, G., Castelli, C., Dalerba, P., Mortarini, R., Rivoltini, L., Marincola, F. M., and Anichini, A. Cancer immunotherapy with peptide based vaccines: what have we achieved? Where are we going? J. Natl. Cancer Inst. (Bethesda), 94: 805-818, 2002.
5. Mukherji, B., Chakraborty, N. G., Sporn, J. R., Kurtzman, S. H., Yamase, H., and Ergin, M. T. Induction of peptide specific and melanoma antigen reactive cytolytic T cells following immunization with MAGE-I peptide pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. USA, 92: 8078-8082, 1995.
6. Chakraborty, N. G., Sporn, J. R., Tortora, A. F., Kurtzman, S. H., Yamasc, H., Ergin, M. T., and Mukherji, B. Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. Clin. Immunol, Immunother., 47: 58-64, 1998.
7. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., and Levy, R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 2: 52-58, 1996.
8. Nestle, F. O., Alijagic, S., Gillet, M., Sun, Y., Grabbe, S., Bummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med., 3: 328-332, 1998.
9. Thurner, B., Haendel, J., Roder, C., Dieckmann, D., Keikavoussi, P., Jonuleit H., Bender, A., Maczec, C., Schriner, D., von den Dricseh, P., Brocker. E. B., Steinman, R. M., Enk, A. H., Kampgen, E., and Schuler, G. Vaccination with Mage-3 A1 peptide-pulsed mature, monocytc-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metasteses in advanced stage IV melanoma. J. Exp. Med., 11: 1669-1678, 1999.
10. + T-cell tolerance by cross-presentation of self antigens. Immunol. Rev., 165: 267-277, 1998.
11. Heath, W. R., and Carbone, F. Crosspresentation in viral immunity and self-tolerance. Nat. Immunol. Rev., 1: 126-134, 2001.
12. Mellman, I. and Steinman, R. M. Dendritic cells: specialized and regulated antigen presenting machines. Cell, 106: 255-258. 2001.
13. Steimnan, R. M., and Nussenzweig, M. C. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. USA, 99: 351-358. 2002.
14. Sallusto, F., and Lanzavecchia. A. Modulating dendritic cells for tolerance, priming, and chronic inflammation. J. Exp. Med., 189: 611-614, 1999.
15. Dhodapkar, M. V., Steinman, R. M., Krasovsky, J. J., Christia, M., and Bhardwaj, N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med., 193: 233-238, 2001.
16. + T cells. Nat. Immunol., 2: 1010-1017, 2001.
17. Coulie, P. G., Brichard, V., van Pel, A., Wolfel, T., Schneider, J., Traversari, C., Mattei, S., De Plaen, E., Lurquin, C., Szikori, J. P. et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 180: 35-42, 1994.
18. Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., and Rosenberg, S. A. Identification of the immunodominant peptides of the MART-I human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med., 180: 347-352. 1994.
19. Rivoltini, L., Kawakami, Y., Sakaguchi, K., Southwood, S., Sette, A., Robbins, P. F., Marineola, F. M., Salgaller, M. L., Yannelli, J. R., Appella, E. et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol., 154: 2257-2265 1995.
20. + T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med., 190: 705-715, 1999.
21. Sallusto, F., and Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage-colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor alpha. J. Exp. Med., 179: 1109-1118, 1994.
22. Chakraborty, A., Li, L., Chakraborty, N. G., and Mukherji, B. Stimulatory and inhibitory differentiation of human myeloid dendritic cells. Clin. Immunol., 94: 88-98, 2000.
23. Klenerman, P., Cerundolo, V., and Dunbar, P. R. Tracking T cells with tetramers: new tales front new tools. Nat. Rev. Immunol., 2: 263-272, 2002.
24. Mukherji, B., Guha, A., Chakraborty, N. G., Sivanandham, M., Nashed, A. L., Sporn, J. R., and Ergin, M. T. Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J. Exp. Med., 169: 1961-1976, 1989.
25. + T cells for efficient tumor cell lysis. Cancer Res., 60: 4446-4452, 2000.
26. Nouri-Shirazi, M., Banehemau, J., Bell, D., Burkeholder, S., Kraus, E. T., Davoust, J., and Palucka, K. A. Dendritic cells capture killed tumor cells and present their antigen to elicit tumor specific immune responses. J. Immunol., 165: 3797-3803, 2000.
27. Jonulcit H., Tuettenberg, A. G., Tuting, T., Schuler, B. T., Stuge, T. B., Paragnik, L., Kandemir, A., Lee, P. P., Schuler, G., Knop, J., and Enk, A. H. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma specific T cell responses in human following intranodal injection. Int. J. Cancer, 93: 243-251, 2001.
28. Lapointe, R., Toso, J. F., Butts, C., Young, H. A., and Hwu, P. Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen-specific T lymphocytes. Eur. J. Immunol., 30: 3291-3298, 2000,
29. den Boer, A. T., Diehl, L., van Mierlo, G. J. D., van der Voort, E. I. H., Fransen, M. F., Krimpenfort, P., Melief, C. J., Offringa, R., and Toes, R. E. M. Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance. J. Immunol., 167: 2522-2528, 2001.
30. Zinkernagel, R. M., and Hengartaer, H. Regulation of the immune response by antigen. Science (Wash. DC), 293: 251-253, 2001.
31. Spiotto, M. T., Yu, P., Rowley, D. A., Nishimura, M. I., Meredith, S. C., Gajewski, T. F., Fu, Y. X., and Schreiber, H. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity, 17: 737-747, 2002.
32. + T cells, after infection. Nat. Immunol., 3: 619-626, 2002.
33. + T cell responses: it's all downhill after their prime... Nat. Immunol., 3: 601-626, 2002.
34. + T cells J. Exp. Med., 186: 239-245, 1997.
35. Morgan, D. J., Kurts, C., Kreuwel H. T., Shortman, K., Heath, W. R., and Sherman, L. A. Ontogeny of T cell tolerance to peripherally expressed antigens. Proc. Natl. Acad. Sci. USA, 96: 3854-3858, 1999.
36. + T cells undergo peripheral tolerance. Immunity, 17: 73-81, 2002.
37. Belz, G. T., Bchrens, G. M., Smith, C. M., Miller, J. F., Jones, C., Lejon, K., Fathman, C. G., Mueller, S. N., Shortman, K., Carbone, F., and Heath, W. R. The CD8 alpha (+) dendritic cell is responsible for inducing peripheral self tolerance to tissue associated antigens. J. Exp. Med., 196: 1099-1104, 2002.
38. Liu, K., Iyoda, T., Saternus, M., Kimura, Y., Inaba, K., and Steinman, R. M. Immune tolerance after delivery of dying cells to dendritic, cells in situ. J. Exp. Med., 196: 1091-1097, 2002.
39. Lutz, M. B., and Schuler, G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol., 23: 445-449, 2002.
40. Roncarolo, M. G., Levings, M. K., and Traversari, C. Differentiation of regulatory cells by immature dendritic cells. J. Exp. Med., 193: F5-F9, 2001.
41. van Parjis, L., and Abbas, A. K. Homeostasis and self-tolerance: turning lymphocytes off, Science (Wash, DC), 280: 243-248, 1998.
42. Lenardo, M., Chan, K. M., Hornung, F., McFarland, H., Siegel, R., Wang, J., and Zheng, L. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu. Rev. Immunol, 17 221-253, 1999.
43. Fuchs, E. J., and Matzinger, P. Is cancer dangerous to: the immune system? Semin. Immunol., 8: 271-280, 1996.
44. Pulendran, B., Banchereau, J., Maraskovsky, E., and Maliszewski, C. Modulating the immune response with dendritic cells and their growth faclors. Trends Immunol., 22: 41-47, 2001.
45. Blankenstein, T., and Schuler, T. Cross-priming versus cross-tolerance: are two signals enough? Trends Immunol., 23: 171-173, 2002.
46. Romero, P., Valmori, D., Pittel, M. J., Zippelius, A., Rimoldi, D., Levy, F., Dutoit, V., Ayyoub, M., Godoy, V. R., Micielin, O., Guillaume, P., Batard, P., Luescher, I. F., Lejeune, F., Lienard, D., Rufer, N., Dietrich, P. Y., Speiser, D. E., and Cerottini, J. C. Antigenicity and immunogenicity of Melan-a/Mart-1 derived peptides as targets for tumor reactive CTL in human melanoma, Immunol. Rev., 188: 81-96, 2002.